# MeiraGTx Holdings MeiraGTx Holdings is an Asset Manager based in New York, United States. ## Overview - **Organization type:** Asset Manager - **Headquarters:** New York, United States - **Region:** North America - **Address:** New York, NY, United States - **Founded:** 2015 - **Assets under management:** Undisclosed - **Website:** meiragtx.com ## Regulatory record - **Reports private funds:** No ## About MeiraGTx Holdings was established in 2015 by Alexandria Forbes, who brought her experience from Kadmon Corporation and a background in developmental biology to the gene therapy arena. The firm went public in 2018 and operates across two primary hubs — a research and corporate base in New York and a manufacturing and R&D facility in London. The London plant provides in-house plasmid, viral vector, and fill-finish capabilities, a structural choice that defines the firm's operational profile. The firm's pipeline targets conditions with high unmet need and clear genetic targets. Its lead programs include botaretigene sparoparvovec for X-linked retinitis pigmentosa, partnered with Johnson & Johnson, and AAV-mediated therapies for achromatopsia and Parkinson's disease. MeiraGTx also developed and deployed its proprietary riboswitch gene regulation platform, which encodes an RNA-based switch to control therapeutic protein expression using an oral small molecule. The geographic footprint spans US and European clinical trial sites, with infrastructure positioned to support both internal programs and third-party contract manufacturing relationships. MeiraGTx runs a lean, integrated team with scientific leadership that includes Forbes and co-founder Keith Gottesdiener. In May 2024, the firm completed the sale of its eye drop asset for the treatment of ocular graft-versus-host disease to VYNE Therapeutics, sharpening its focus on gene therapy and manufacturing. Prior partnerships include a significant collaboration with Janssen, which took an equity stake and shared development costs on the inherited retinal disease program. MeiraGTx also operates through subsidiary entities that hold specific assets and intellectual property for its riboswitch and clinical-stage pipeline. What separates MeiraGTx from a conventional biotech platform is its deliberate vertical integration. The London GMP plant is not a cost center layered onto a discovery engine — it is the core of the value proposition, allowing the firm to control vector design, process development, and patient dosing without reliance on external CDMOs. This in-house manufacturing capability also positions MeiraGTx as a potential contract manufacturer for other gene therapy developers, adding a service-layer revenue stream alongside its clinical pipeline. ## Sectors - Digital Health - Healthcare Services ## Offices - London, United Kingdom ## People - Alexandria Forbes — President and Chief Executive Officer ## Questions ### Who runs investment and strategic decisions at MeiraGTx Holdings? Alexandria Forbes serves as President and CEO and co-founded the company in 2015. She sets the strategic direction across pipeline prioritization, partnership structuring, and the firm's vertically integrated manufacturing model. The board includes representation from major partners, including Johnson & Johnson through its Janssen collaboration. ### What is MeiraGTx's proprietary riboswitch platform? The riboswitch platform uses an RNA-based switch encoded within the gene therapy vector to regulate therapeutic protein expression. An oral small molecule controls the switch, enabling dose titration after a one-time gene therapy administration. This platform is distinct from conventional gene therapy constructs that offer no post-delivery control over expression levels. ### Does MeiraGTx operate its own manufacturing capacity? Yes. MeiraGTx runs a GMP manufacturing facility in London capable of plasmid production, viral vector manufacturing, and filling and finishing. This in-house capacity supports both its internal clinical pipeline and positions the firm to pursue third-party contract manufacturing opportunities, creating a revenue stream outside its wholly owned programs. ### How is MeiraGTx related to Johnson & Johnson? Johnson & Johnson, through its Janssen arm, partnered with MeiraGTx on the development of botaretigene sparoparvovec for X-linked retinitis pigmentosa. The collaboration included an equity investment in MeiraGTx and shared development costs. This partnership validates the firm's clinical-stage program through one of the largest pharmaceutical companies globally. ### Which disease areas does MeiraGTx target? MeiraGTx concentrates on inherited retinal diseases — including X-linked retinitis pigmentosa and achromatopsia — as well as neurodegenerative conditions such as Parkinson's disease and xerostomia stemming from radiation therapy. The firm selects indications with well-characterized genetic drivers and high unmet medical need. ### What is the firm's posture on external partnerships and co-development? MeiraGTx actively pursues partnerships with large pharmaceutical companies, as demonstrated by the Janssen collaboration, while retaining full ownership of specific assets and its manufacturing infrastructure. The firm also monetizes non-core assets through divestitures, such as the sale of its eye drop program to VYNE Therapeutics in 2024. ## Related profiles - [Mercantile Bank Corp](https://altss.com/profile/mercantile-bank-corp) - [ATII Holdings](https://altss.com/profile/atii-holdings-inc) --- Last updated: 2026-06-03T20:00:00.000Z Canonical page: https://altss.com/profile/meiragtx-holdings-plc Maintained by Altss — https://altss.com — methodology: https://altss.com/methodology